SEC Form 4 · accession 0001104659-19-013173
Kiniksa Pharmaceuticals International, plc · KNSA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas W. Beetham
Officer — EVP & Chief Legal Officer
Period of report
Mar 4, 2019
Accepted (ET)
Mar 6, 2019 · 6:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001730430
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share OptionF1 | $17.92 | Mar 4, 2019 | A | 42,000 | A | — | Mar 3, 2029 | Class A Common Shares | 42,000 | 42,000 | D |
Explanation of responses
- F1The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 4, 2019.